Antagonistic human FcyRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo
- Submitting institution
-
University of Southampton
- Unit of assessment
- 5 - Biological Sciences
- Output identifier
- 20808965
- Type
- D - Journal article
- DOI
-
10.1016/j.ccell.2015.03.005
- Title of journal
- Cancer Cell
- Article number
- -
- First page
- 473
- Volume
- 27
- Issue
- 4
- ISSN
- 1535-6108
- Open access status
- Out of scope for open access requirements
- Month of publication
- April
- Year of publication
- 2015
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
31
- Research group(s)
-
-
- Citation count
- 60
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Smyth - My role was in the production of transgenic mice expressing the human Fc FcγRIIB – this was needed to produce a suitable animal model to test the proof of principle of the above and show other immune responses were maintained. I also contributed to the drafting and critique of the final manuscript.
- Non-English
- No
- English abstract
- -